34 companies, 1 interpreter! Insight, foresight
and recommendation 


09/30/2013 - 8:42pm

Hyatt Regency, Cambridge, MA
Henry McCusker

08/19/2013 - 6:52pm

Osiris Chairman acquires stock

Osiris (OSIR) chairman Peter Friedli purchased 1 million shares of Osiris on 8/14/13 at $11.00 per share.

Read more
07/08/2013 - 10:11pm

A successful €23 million initial public offering  (IPO) last week was based on highly questionable research, according to a group of UK physicians who have scrutinized the available data. In addition, one of the researchers, a prominent European cardiologist, failed to disclose in a key paper that he helped to start, and held a significant interest in, the company, Cardio3 BioSciences.

07/05/2013 - 10:30am

Researchers have yet to realise the old dream of regenerating organs. But they are getting closer.

07/04/2013 - 9:08pm

Scientists used human stem cells to create precursors to human livers like those in fetuses, and the early organs functioned as livers when transplanted into mice.

06/13/2013 - 7:46am

Researchers and biotech firms say European court ruling will deter investors from funding new cures

06/10/2013 - 6:40pm

Have Scientists Finally Found Truly Pluripotent Adult Stem Cells?  John Farrell reports in that a new research paper in PLOS|One this past week claims to have found a fatty tissue source of pluripotent adult stem cells.

06/06/2013 - 7:24am

Pluristem CEO Zami Aberman faced the media to answer questions on Pluristem’s (PSTI) announcement that its PII Intermittent Claudification study in the U.S. has been put on hold by the U.S. Food and Drug Administration.

05/23/2013 - 8:10pm

In the near future, chronic heart disease patients in the U.S. could find themselves in an outpatient clinic, getting a new treatment that is not much more complicated than donating platelets at the Red Cross.  Say hello to the Celution system from Cytori Therapeutics, which is currently being tested in the U.S.